Latest news with #TadaImages
Yahoo
5 days ago
- Business
- Yahoo
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained
Cellectar Biosciences, Inc. (NASDAQ:CLRB) stock is trading higher on Wednesday. As per data from Benzinga Pro, session volume stands at 361.96 million versus an average volume of 968.03k. What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company's iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).Why It Matters: WM is the dominant subtype of lymphoplasmacytic lymphoma. Data from the Phase 2 CLOVER WaM study, including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2%, which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented during the 66th Annual American Society of Hematology Conference in December 2024. As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation and Orphan Drug Designation. The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I 131 for r/r WM and PRIME Designation for WM. What's Next: Separately, the company has provided the EMA with a data package that includes extensive supportive preclinical, regulatory, and manufacturing data and safety and efficacy data from the CLOVER WaM Phase 2b clinical trial. The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval. In late July 2025, the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application. Price Action: CLRB stock is trading higher by 57.9% to $0.43 at last check Wednesday. Read Next:Photo by Tada Images via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
14-05-2025
- Entertainment
- New York Post
Gen Z co-opted the smiley face emoji, but beware — it means something totally different to them
Smiling at Gen Z? Better watch your back. What used to be the universal symbol of warmth and joy has taken a sinister turn — at least in the eyes of Gen Z. The classic smiley face emoji now means something completely different to those under 30. Instead of conveying happiness, the grinning yellow face is now seen as dismissive, passive-aggressive, or straight-up sarcastic. And if you're sending it to younger colleagues or friends, it could be rubbing them the wrong way. Hafeezat Bishi, a 21-year-old intern, recently told the Wall Street Journal that she was taken aback when her older coworkers used the smiley emoji in emails and texts. 4 Flashing a smile at Gen Z? Brace yourself. The classic symbol of warmth and friendliness has morphed into something far snarkier — at least to them. Emojipedia 'I had to remember they are older, because I use it sarcastically,' Bishi said, explaining that she often views the emoji as conveying a 'side-eye smile' rather than genuine enthusiasm. Meanwhile, Sara Anderson, a 31-year-old cheerleading coach, told the outlet that she regularly includes the emoji to add 'lightness' to her messages. But that's exactly the disconnect — what seems friendly to older folks can come off as phony or even biting to the younger crowd. According to Erica Dhawan, author of 'Digital Body Language: How to Build Trust and Connection, No Matter the Distance,' older generations tend to take emojis at face value, while younger 'digital natives' assign entirely different meanings. 4 Author Erica Dhawan says older folks read emojis by the book — but for Gen Z, those little icons pack a whole new punch. Tada Images – 'People over 30 tend to use emoji according to their dictionary,' Dhawan told the Journal, emphasizing that for Gen Z, emoji meanings have evolved into a whole new lexicon. But the generational gap isn't just about smileys. Back in March, Amit Kalley, founder of mom-and-dad support site For Working Parents, warned that emojis have become a covert language for teens to communicate everything from drug slang to hate speech. 'It's far from an exhaustive list, but it's based on common emojis used to say something very different to what you'd think,' Kalley wrote on Instagram, pointing to a 'periodic table of emojis' that decodes the hidden messages. 4 What looks like a friendly emoji to boomers and millennials? To Gen Z, it could mean a fake smile or a not-so-subtle jab. DisobeyArt – And the emoji evolution doesn't end there. A recent study from Oklahoma State University found that emoji use can reveal a lot more about your personality than you might think. Researchers surveyed 285 undergraduates, mostly 20-year-olds, to see how their emoji habits aligned with personality traits. 4 To Gen Z, that classic smiley face emoji isn't all sunshine — it's more of a smug, side-eye smirk that can come off as passive-aggressive in texts like above. 'Emoji use may be related to strategies to manipulate the perceptions of others and to present a positive impression of oneself,' the study said, suggesting that what you send could say more about you than you realize. So, the next time you slap a smiley face emoji on a message to Gen Z, think twice — it might not come off as cheery as you'd hoped.
Yahoo
13-05-2025
- Automotive
- Yahoo
What's Going On With NIO Stock On Tuesday?
NIO Inc. (NYSE:NIO) shares are trading lower on Tuesday. The firm revealed that its advanced steer-by-wire system, featured in the ET9 executive sedan, has secured a key regulatory approval in Europe, reports CnEV Post, citing a statement from CEO William Li on Weibo. This development positions the electric vehicle manufacturer as a global frontrunner in deploying next-generation driving technologies. The SBW technology on the ET9 has received the E-Mark certification under the United Nations Economic Commission for Europe framework, following assessment by the Spanish automotive certification group Applus marks the first time the organization has endorsed an SBW-enabled vehicle in the region. NIO launched the ET9, its most premium offering to date, during Nio Day 2024. Priced at RMB 788,000 (approximately $109,560), the four-seater sedan began reaching customers in China at the end of March, CnEV Post adds. The company delivered 810 units in April, its first full delivery month, according to CnEVPost data. Alongside the ET9 milestone, NIO is refreshing several key models in its lineup. Beginning May 10, customers in China can place pre-orders for updated versions of the ES6 SUV, EC6 coupe SUV, and the ET5 and ET5 Touring sedans. Showrooms will simultaneously unveil the revamped ES6 and EC6 models. NIO recorded 23,900 vehicle deliveries in April, a 53% year-over-year increase. The surge in shipments indicates strong demand, even as the company invests in innovative features like SBW and explores international market opportunities. Price Action: NIO shares are trading lower by 2.02% to $4.115 at last check on Tuesday. Photo by Tada Images via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NIO (NIO): Free Stock Analysis Report This article What's Going On With NIO Stock On Tuesday? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-04-2025
- Business
- Yahoo
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate response to standard therapies. The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks compared to placebo. In the Phase 3b APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores. Also Read: Data were consistent with the well-established safety profile of Tremfya with no new safety signals identified. APEX is a Phase 3b study with long-term extension data through three years that will further assess the sustained efficacy of Tremfya on inhibition of structural damage in patients with active PsA. Results from the APEX study are being prepared for presentation at upcoming medical congresses. Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory. Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Johnson & Johnson, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Johnson & Johnson, the 200-day moving average sits at $156.5, according to Benzinga Pro, which is above the current price of $155.82. For more on charts and trend lines, see a description here. Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable. Price Action: JNJ stock is down 3.51% at $154.21 at the last check Friday. Read Next:Photo by Tada Images via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? JOHNSON & JOHNSON (JNJ): Free Stock Analysis Report This article Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
